Solventum (SOLV) stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 78 to 81. The healthcare solutions stock debut Mar. 26.

IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.

History shows that the best stocks typically have an 80 or higher RS Rating in the early stages of their moves.

Hone Your Stock-Picking Skills By Focusing On These Factors

Is Solventum Stock A Buy?

Solventum stock broke out earlier, but is now about 4% below the prior 72.40 entry from a cup without handle. If a stock you're tracking clears a buy point then falls 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new chart pattern and entry price. Also understand that the most recent consolidation is a later-stage base, and those involve more risk.

The healthcare products firm showed -36% earnings growth last quarter, while sales growth came in at 0%. Look for the next report on or around Nov. 7.

Solventum stock earns the No. 26 rank among its peers in the Medical-Products industry group. Bioventus (BVS), Insulet (PODD) and Boston Scientific (BSX) are among the top 5 highly rated stocks within the group.

YOU MAY ALSO LIKE:

MarketSurge's Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks